In 2021, according to the Times, insurance carriers reported that 42,000 minors were diagnosed with gender dysphoria and “4,780 patients with that diagnosis were put on puberty blockers covered by insurance.”

Now, “concerns are growing among some medical professionals about the consequences of the drugs” used by many clinics and physicians to treat children as young as 6 years old.

The Times commissioned an analysis of “seven studies from the Netherlands, Canada and England involving about 500 transgender teens from 1998 through 2021,” and it learned that while teens were on blockers, they “did not gain any bone density, on average — and lost significant ground compared to their peers.”

Puberty blockers may somehow disrupt a formative period of mental growth. With adolescence comes critical thinking, more sophisticated self-reflection and other significant leaps in brain development. Sex hormones have been shown to affect social and problem-solving skills. It’s believed that brain growth is connected to gender identity, but research in these areas is still very new.”